These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26593977)

  • 21. Bicyclic octahydrocyclohepta[b]pyrrol-4(1H)one derivatives as novel selective anti-hepatitis C virus agents.
    Kaushik-Basu N; Ratmanova NK; Manvar D; Belov DS; Cevik O; Basu A; Yerukhimovich MM; Lukyanenko ER; Andreev IA; Belov GM; Manfroni G; Cecchetti V; Frick DN; Kurkin AV; Altieri A; Barreca ML
    Eur J Med Chem; 2016 Oct; 122():319-325. PubMed ID: 27376494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple effects of Honokiol on the life cycle of hepatitis C virus.
    Lan KH; Wang YW; Lee WP; Lan KL; Tseng SH; Hung LR; Yen SH; Lin HC; Lee SD
    Liver Int; 2012 Jul; 32(6):989-97. PubMed ID: 22098176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C treatment: an incipient therapeutic revolution.
    deLemos AS; Chung RT
    Trends Mol Med; 2014 Jun; 20(6):315-21. PubMed ID: 24636306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cell-based, microplate colorimetric screen identifies 7,8-benzoflavone and green tea gallate catechins as inhibitors of the hepatitis C virus.
    Fukazawa H; Suzuki T; Wakita T; Murakami Y
    Biol Pharm Bull; 2012; 35(8):1320-7. PubMed ID: 22863932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
    Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
    Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.
    Paeshuyse J; Kaul A; De Clercq E; Rosenwirth B; Dumont JM; Scalfaro P; Bartenschlager R; Neyts J
    Hepatology; 2006 Apr; 43(4):761-70. PubMed ID: 16557546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Caffeine inhibits hepatitis C virus replication in vitro.
    Batista MN; Carneiro BM; Braga AC; Rahal P
    Arch Virol; 2015 Feb; 160(2):399-407. PubMed ID: 25491197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry.
    Ciesek S; von Hahn T; Colpitts CC; Schang LM; Friesland M; Steinmann J; Manns MP; Ott M; Wedemeyer H; Meuleman P; Pietschmann T; Steinmann E
    Hepatology; 2011 Dec; 54(6):1947-55. PubMed ID: 21837753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.
    Wagoner J; Morishima C; Graf TN; Oberlies NH; Teissier E; Pécheur EI; Tavis JE; Polyak SJ
    PLoS One; 2011 Jan; 6(1):e16464. PubMed ID: 21297992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New hepatitis C therapies: the toolbox, strategies, and challenges.
    Pawlotsky JM
    Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are statins a viable option for the treatment of infections with the hepatitis C virus?
    Verpaalen B; Neyts J; Delang L
    Antiviral Res; 2014 May; 105():92-9. PubMed ID: 24613180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Subgenomic replications of hepatitis C virus (HCV): new possibilities for hepatitis C prophylaxis and treatment].
    Puig-Basagoiti F; Sáiz JC
    Gastroenterol Hepatol; 2001 Dec; 24(10):506-10. PubMed ID: 11730621
    [No Abstract]   [Full Text] [Related]  

  • 35. Plant-derived antivirals against hepatitis c virus infection.
    Jardim ACG; Shimizu JF; Rahal P; Harris M
    Virol J; 2018 Feb; 15(1):34. PubMed ID: 29439720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety of daclatasvir for the treatment of hepatitis C.
    Jafri SM; Gordon SC
    Expert Opin Drug Saf; 2015; 14(11):1787-97. PubMed ID: 26571362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitors.
    Girijavallabhan VM; Alvarez C; Bennett F; Chen L; Gavalas S; Huang Y; Kim SH; Kosinski A; Pinto P; Rizvi R; Rossman R; Shankar B; Tong L; Velazquez F; Venkatraman S; Verma VA; Kozlowski J; Shih NY; Piwinski JJ; MacCoss M; Kwong CD; Bansal N; Clark JL; Fowler AT; Kezar HS; Valiyaveettil J; Reynolds RC; Maddry JA; Ananthan S; Secrist JA; Li C; Chase R; Curry S; Huang HC; Tong X; Njoroge FG; Arasappan A
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5652-7. PubMed ID: 22858143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication.
    Stachulski AV; Pidathala C; Row EC; Sharma R; Berry NG; Lawrenson AS; Moores SL; Iqbal M; Bentley J; Allman SA; Edwards G; Helm A; Hellier J; Korba BE; Semple JE; Rossignol JF
    J Med Chem; 2011 Dec; 54(24):8670-80. PubMed ID: 22059983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.
    Rockstroh JK
    Liver Int; 2015 Jan; 35 Suppl 1():51-5. PubMed ID: 25529087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple effects of silymarin on the hepatitis C virus lifecycle.
    Wagoner J; Negash A; Kane OJ; Martinez LE; Nahmias Y; Bourne N; Owen DM; Grove J; Brimacombe C; McKeating JA; Pécheur EI; Graf TN; Oberlies NH; Lohmann V; Cao F; Tavis JE; Polyak SJ
    Hepatology; 2010 Jun; 51(6):1912-21. PubMed ID: 20512985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.